BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Parkinson's disease clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for Parkinson disease: 208 (119 sponsors; 30 newly posted in the last 180 days, 16 stopped in the last 180 days; 21 new-entrant sponsors). Momentum score 10.1, rank 68 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 7, Phase 1 34, Phase 2 67, Phase 3 36, Phase 4 2, N/A 62.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Merck Sharp & Dohme LLC MRK | 41 | P3 23, P2 15, NA 1, P1 2 | 0 | 5 |
| Hoffmann-La Roche | 4 | P3 1, P2 3 | 1 | 0 |
| AstraZeneca AZN | 3 | P2 1, P1 1, P3 1 | 0 | 0 |
| BlueRock Therapeutics BPRE | 2 | NA 1, P3 1 | 0 | 1 |
| NeuroDerm Ltd. | 2 | P3 1, P2 1 | 0 | 0 |
| Annovis Bio Inc. ANVS | 1 | P3 1 | 0 | 0 |
| Biohaven Therapeutics Ltd. BHVN | 1 | P3 1 | 0 | 0 |
| Cerevance | 1 | P3 1 | 0 | 0 |
| Hangzhou PhecdaMed Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| Jazz Pharmaceuticals JAZZ | 1 | P3 1 | 0 | 0 |
| MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | 1 | P3 1 | 0 | 0 |
| Ono Pharmaceutical Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| Taiho Pharmaceutical Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| Zhejiang Vimgreen Pharmaceuticals, Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| InSightec | 9 | NA 9 | 1 | 0 |
| AbbVie ABBV | 8 | NA 8 | 0 | 3 |
| iRegene Therapeutics Co., Ltd. | 5 | P1 2, P2 3 | 0 | 1 |
| AskBio Inc | 3 | P2 2, NA 1 | 0 | 0 |
| Boston Scientific Corporation BSX | 3 | NA 3 | 0 | 0 |
| MODAG GmbH new entrant | 3 | EARLY_P1 3 | 3 | 2 |
| Abbott Medical Devices | 2 | NA 2 | 0 | 0 |
| AC Immune SA ACIU | 2 | EARLY_P1 1, P2 1 | 0 | 1 |
| Bayer | 2 | P2 1, NA 1 | 0 | 0 |
| Bial - Portela C S.A. | 2 | NA 2 | 0 | 0 |
| BioNTech SE BNTX | 2 | P1 1, P2 1 | 0 | 0 |
New-entrant sponsors: Hangzhou PhecdaMed Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Zhejiang Vimgreen Pharmaceuticals, Ltd., MODAG GmbH.
Recently stopped trials
- NCT04428151 Merck Sharp & Dohme LLC - terminated: Business Reasons Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monother
- NCT06193421 Agyany Pharma LTD - terminated: Sponsor's decision High-Dose Ambroxol in GBA1-Related Parkinson
- NCT05382325 Merck Sharp & Dohme LLC - terminated: Business Reasons A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors
- NCT06003608 Nimble Science Ltd. - terminated: Study recruitment phase exceeded the time allotted Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease
- NCT07313176 Britannia Pharmaceuticals Ltd. - terminated: Following a reassessment, it was concluded that continuation of the study would no longer achieve its scientific objectives originally set o Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Diseas
- NCT03834493 Merck Sharp & Dohme LLC - terminated: The study stopped due to futility Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Cast
- NCT04191096 Merck Sharp & Dohme LLC - terminated: The study stopped due to futility Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo
- NCT04738487 Merck Sharp & Dohme LLC - terminated: Business Reasons Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell De
- NCT04191135 Merck Sharp & Dohme LLC - terminated: Business Reasons Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy
- NCT05665595 Merck Sharp & Dohme LLC - terminated: Business Reason A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Partic
- NCT04246177 Merck Sharp & Dohme LLC - terminated: Business Reasons Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoem
- NCT04949256 Merck Sharp & Dohme LLC - terminated: Trial was rendered as cancelled work ongoing in the book of business. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Me
- NCT05931484 Forest Hills Lab - withdrawn: Has yet to begin and may not so halting to avoid participant outreach Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.
- NCT03598608 Merck Sharp & Dohme LLC - terminated: Business Reason Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Parti
- NCT07011771 Capsida Biotherapeutics, Inc. - withdrawn: Per protocol stopping rule was met for a separate trial for a different disease state and different experimental therapy that utilized a sim A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-28 est. | P2 | TrueBinding, Inc. | NCT06773962 A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | Parkinson's Disease (PD) | active not recruiting | 62 |
| 2026-12 est. | P2 | iRegene Therapeutics Co., Ltd. | NCT07028632 The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease | Parkinson Disease (PD) | not yet recruiting | 30 |
| 2026-12 est. | P1/P2 | EicOsis Human Health Inc. | NCT07142044 Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study) | Parkinson's Disease (PD) | recruiting | 18 |
| 2026-12-31 est. | P2 | Hillhurst Biopharmaceuticals, Inc. | NCT07005180 Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease | Parkinson Disease | recruiting | 36 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-10 est. | P1/P2 | Shanghai Vitalgen BioPharma Co., Ltd. | NCT06480461 A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease | Parkinson's Disease | active not recruiting | 39 |
| 2026-09-02 | P2 | Il-Yang Pharm. Co., Ltd. | NCT04691661 Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease | Parkinson Disease | active not recruiting | 43 |
| 2026-08-10 | P2 | BioArctic AB | NCT06671938 Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy | Parkinson Disease; Multiple System Atrophy | completed | 38 |
| 2026-08 est. | P3 | Cerevance | NCT06553027 To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | Parkinson Disease | active not recruiting | 330 |
| 2026-06-17 | P1/P2 | Capsida Biotherapeutics, Inc. | NCT07011771 A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease | GBA1 Parkinson Disease | withdrawn |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "Parkinson disease"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.